Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Travellers' diarrhoea. Which antimicrobial?

Herbert L DuPont1

  • 1Center for Infectious Diseases, University of Texas Medical School and School of Public Health, 6431 Fannin, 1.729JFB, Houston, Texas, 77030, USA.

Drugs
|June 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbiome alterations during and after international travel.

Journal of travel medicine·2025
Same author

Leaders behind the launching of the international society of travel medicine, the journal of travel medicine and helping to define a new medical discipline.

Journal of travel medicine·2025
Same author

Re-visiting bismuth subsalicylate for the prevention of travellers' diarrhoea.

Journal of travel medicine·2025
Same author

Microbiota restoration therapies for recurrent <i>Clostridioides difficile</i> infection reach an important new milestone.

Therapeutic advances in gastroenterology·2024
Same author

The Importance of a Healthy Microbiome in Pregnancy and Infancy and Microbiota Treatment to Reverse Dysbiosis for Improved Health.

Antibiotics (Basel, Switzerland)·2023
Same author

The potential for development of clinically relevant microbial resistance to rifaximin-α: a narrative review.

Clinical microbiology reviews·2023
Same journal

The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

Drugs·2026
Same journal

Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

Drugs·2026
Same journal

Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

Drugs·2026
Same journal

Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

Drugs·2026
Same journal

Relacorilant: First Approval.

Drugs·2026
Same journal

Developmental Progress and Future Potential for Inhaled Biologics in the Treatment of Respiratory Diseases.

Drugs·2026
See all related articles

Travelers" diarrhea affects 40% of those visiting tropical regions, often caused by bacterial pathogens. Effective treatment involves antimicrobial agents like cotrimoxazole or fluoroquinolones, alongside rehydration and symptomatic relief.

Area of Science:

  • Infectious Diseases
  • Travel Medicine
  • Microbiology

Background:

  • Travelers' diarrhea affects approximately 40% of individuals traveling from industrialized to developing tropical and subtropical areas.
  • Bacterial pathogens are the primary cause of travelers' diarrhea in most cases.
  • Understanding effective antimicrobial treatments is crucial for managing this common travel-related illness.

Purpose of the Study:

  • To identify effective antimicrobial agents for treating bacterial travelers' diarrhea.
  • To provide recommendations for managing symptoms and preventing illness in at-risk travelers.
  • To evaluate the role of antimicrobial therapy and chemoprophylaxis in travelers' diarrhea.

Main Methods:

  • Review of antimicrobial activity against common bacterial pathogens causing travelers' diarrhea.

Related Experiment Videos

  • Analysis of treatment protocols including rehydration, symptomatic relief, and antimicrobial therapy.
  • Consideration of chemoprophylaxis for specific high-risk situations.

    • Main Results:

    • Cotrimoxazole (trimethoprim/sulfamethoxazole) shows high activity during summer months in Mexico; fluoroquinolones are recommended for other regions or times.
    • Treatment involves rehydration, symptomatic management (e.g., loperamide for afebrile, non-dysenteric cases), and antimicrobial therapy.
    • Antimicrobial therapy is the most critical component, administered as a single dose or for 3 days.

    Conclusions:

    • Antimicrobial agents are essential for treating bacterial travelers' diarrhea, with specific recommendations based on region and time.
    • Combined symptomatic and antimicrobial treatment is optimal for most cases.
    • Chemoprophylaxis with reduced antimicrobial dosage may be considered in select high-risk scenarios but is not recommended for the majority of travelers.